FDA approves generic aromatase inhibitor
June 29, 2010
Bloomberg Businessweek reports that the FDA has approved two generic forms of AstraZeneca's Arimidex, an aromatatse inhibitor used as treatment for postmenopausal, estrogen receptor-positive breast cancer. According to the report, the FDA has approved two generic versions containing anastrozole, the active ingredient in Arimidex - one produced by Teva Pharmaceutical Industries Ltd., and one by Mylan Inc.
MYTHS VS. TRUTHS
Brush up on your breast cancer myths and truths. Find out if you know more about breast cancer than the American public.
I'll Talk
Speak up and out about breast cancer. Say, "I'll Talk" and commit to a conversation about breast cancer with people you know and care about.
Understanding Research and Evidence